Blog

Flavio G Rocha: Dose density in neoadjuvant treatment for PDAC

Flavio Rocha/X

Feb 12, 2025, 17:33

Flavio G Rocha: Dose density in neoadjuvant treatment for PDAC

Flavio G Rocha, Hedinger Chair of Surgical Oncology and Physician-in-Chief OHSU Knight Cancer Institute, shared on X about recent paper by Sameer Patel et al., titled “Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505” published on ACS Journals.

Authors: Sameer H. Patel, Sarah Colby, Davendra Sohal, Katherine A. Guthrie, Lisa A. Kachnic, E. Gabriela Chiorean, Andrew M. Lowy, Flavio G. Rocha, Howard S. Hochster, Philip A. Philip, Syed A. Ahmad

“Dose density in neoadjuvant treatment for PDAC

A landmark analysis of SWOG S1505
DD >85% pre or DD >70% periop lead to OS benefit

Kudos to investigators and lead author Dr. Sameer Patel.“

Andrew M. Lowy cancer Davendra Sohal E. Gabriela Chiorean Flavio G. Rocha Howard S Hochster Katherine A. Guthrie Lisa A. Kachnic OncoDaily Oncology Philip A. Philip Sameer H. Patel Sarah Colby Syed A. Ahmad

ACT for Children: Tackling Inequities in Childhood Cancer Through Unique Global Collaboration

Richard Gere and Alejandra Gere to Join Second Global OncoThon on February 15 for Fight Against Childhood Cancer

Mesothelioma Guideline Updates from ASCO 2024: Key Advances in Diagnosis and Treatment

Oncologist Near Me - Lynn Schuchter: A Pioneering Leader in Cancer Care and Melanoma Research

NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%